Livionex Oral Microbiome and Dental Plaque Control in HSCT Recipients
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
Children undergoing chemotherapy, radiation treatment and Hematopoietic Stem Cell
Transplantation (HSCT) have significant difficulties achieving good oral hygiene and dental
plaque control. HSCT recipients are at a significant risk for bacteremia and sepsis.
Livionex® toothpaste was shown to be effective in reducing dental plaques while containing no
additives found in other toothpastes that can cause increased gingival irritation. The
investigators hypothesize that improved oral hygiene and better plaque control in pediatric
patients receiving chemo/radiation treatment or HSCT may result in reduced oral inflammation,
decreased amount of oral bacterial pathogens, and reduced risk of oral-pathogen related
systemic bacterial infections. The overall goal of this prospective randomized (2:1) pilot
study is to determine whether incorporation of the Livionex® toothpaste in the research
regimen could reduce dental plaque.